Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
September 30 2022 - 1:00PM
Information on the Total Number of Voting Rights (Denominator)
following Conversion Notice from NEGMA
Negma Group has converted 160 convertible bonds in
Oxurion resulting in a EUR 400,000 capital increase. This is part
of Negma Group’s EUR 30 million Capital Commitment1 that will allow
Oxurion to focus on progressing its novel and differentiated back
of the eye drug candidate targeting potential market opportunities
of over USD 5 billion.
Leuven,
BELGIUM, Boston,
MA, US – September
30,
2022 –
07.00
PM CET – In accordance with
article 15 of the Belgian Act of May 2, 2007 on the disclosure of
major participations in issuers of which shares are admitted to
trading on a regulated market and regarding miscellaneous
provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or
“Oxurion”), announces the below information, following the issuance
of (i) 1,052,631 new ordinary shares on September 5, 2022, for a
total amount of EUR 200,000, as the result of the conversion of 80
convertible bonds pursuant to the Capital Commitment entered into
with Negma Group, and (ii) 1,052,631 new ordinary shares on
September 13, 2022, for a total amount of EUR 200,000, as the
result of the conversion of 80 convertible bonds pursuant to the
Capital Commitment entered into with Negma Group.
Following completion of the capital increase
through the conversion of the convertible bonds, the total number
of shares issued by Oxurion amounts to 55,159,533 outstanding
ordinary shares carrying voting rights (compared to 53,054,271
outstanding ordinary shares previously). This number will be used
as the denominator for the calculation of the percentages of
shareholdings.
Therefore, Oxurion publishes the following
updated information:
|
70,906,161.32 |
- Total number of securities with
voting rights (all ordinary shares)
|
55,159,533 |
- Total number of ordinary shares (=
denominator)
|
55,159,533 |
- Number of outstanding, granted
rights to subscribe to securities carrying voting rights not yet
issued:
|
|
- 719,500 subscription rights (“SRs”)
issued on November 20, 2017, entitling their holders to subscribe
to a total number of 719,500 securities carrying voting rights (all
ordinary shares);
- 60,000 SRs issued on December 23,
2020, entitling their holders to subscribe to a total number of
60,000 securities carrying voting rights (all ordinary
shares);
- 1,007,250 SRs issued on April 14,
2021, entitling their holders to subscribe to a total number of
1,007,250 securities carrying voting rights (all ordinary
shares);
- 550,000 SRs issued on September 22,
2021, entitling their holders to subscribe to a total number of
550,000 securities carrying voting rights (all ordinary
shares);
- 739,499 SRs issued on December 30,
2021, entitling their holders to subscribe to a total number of
739,499 securities carrying voting rights (all ordinary
shares);
- 40 convertible bonds issued on
August 5, 2022, entitling their holder (Negma Group) to subscribe
to a total number of securities carrying voting rights (all
ordinary shares) in accordance with the terms and conditions set
forth in the issuance and subscription agreement entered into
between the Company and Negma Group on August 26, 2021;
- 1,080 convertible bonds issued on
September 5, 2022, entitling their holder (Negma Group) to
subscribe to a total number of securities carrying voting rights
(all ordinary shares) in accordance with the terms and conditions
set forth in the issuance and subscription agreement entered into
between the Company and Negma Group on August 26, 2021, and the
addendum thereto dated September 2, 2022; and
- 100 convertible bonds issued on
December 20, 2021, entitling their holders (Kreos Capital VI (UK)
Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax
Medison Finance (Cayman) L.P.) to subscribe to a total number of
securities carrying voting rights (all ordinary shares) in
accordance with the terms and conditions of these convertible bonds
as attached to the Agreement for the provision of a Loan Facility
entered into between the Company, Kreos Capital VI (UK) Limited,
Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance
(Cayman) L.P., on November 21, 2021.
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michaël DillenChief Business
OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
US Conway CommunicationsBeth
Kurthbkurth@conwaycommsir.com ICR WestwickeChristopher
BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com |
1 Press release Oxurion, 06/04/2021 and Press release Oxurion,
02/09/2022
- OXUR PR_Voting rights (ENG)_20220930
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Apr 2023 to Apr 2024